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of functional and imaging end points. Surprisingly, our study showed that combining G-CSF and BM MNC at 48 hours had significant adverse effects on the neurological outcome. Further mechanistic experiments indicated an interaction of granulocytes, which were massively mobilized by G-CSF, and transplanted BM MNC in the spleen. The consecutive spillover of granulocytes may finally explain the unfavorable outcome.
Although our experiments failed to provide a novel preclinical approach for stroke, it emphasizes the importance of the immune system for the development and translation of stroke therapies.
Materials and Methods
A detailed description of materials and methods is provided in the online-only Data Supplement.
Experimental Stroke
Animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by legal authorities (TVV 12/11). Spontaneously hypertensive rats (SHR; Charles River, Sulzfeld, Germany; 12 weeks of age) were anesthetized with ketamine/xylazine and subjected to permanent right middle cerebral artery occlusion (pMCAO).
Experimental Set Up and Treatment
Animals were randomly assigned to following experimental groups:
(1) G-CSF monotherapy (G-CSF; n=18) with daily intraperitoneal injection of 50 μg/kg body weight G-CSF for 5 days starting 1 hour after pMCAO; (2) G-CSF plus intravenous transplantation of 1.5×10E7 BM MNC per kilogram body weight at 6 hours after pM-CAO (G-CSF+BM MNC 6 hours; n=18); (3) G-CSF plus intravenous transplantation of 1.5×10E7 BM MNC per kilogram body weight at 48 hours after pMCAO (G-CSF+BM MNC 48 hours; n=18); (4) control group (control; n=18) receiving phosphate buffered saline instead of G-CSF and BM MNC. Stroke induction, treatments, and analyses were performed by investigators blinded to group allocation.
Study End Points
Infarct volume and space-occupying effect were determined by magnetic resonance imaging at days 1, 3, 7, and 30. Neurological deficits were assessed by the adhesive removal test at days 2, 7, 14, 21, and 28. Circulating leukocytes were identified by specific antigens (Table I in the online-only Data Supplement) within the first week after stroke using flow cytometry. Cytokine levels were repeatedly measured by multiparametric enzyme-linked immunosorbent assay. At day 30 after stroke, expressions of plasticity and inflammation-related genes were assessed by quantitative real-time polymerase chain reaction. T cells were visualized by immunofluorescence staining and counted within the infarct border and the entire ischemic hemisphere.
Biodistribution and Short-Term Effects of Cell Transplantation
In a subgroup analysis, animals were randomly assigned to groups 1, 3, and 4 (n=3 per group). Distribution of PKH26-labeled BM MNC and immune cell frequencies were determined in the blood, BM, and single cell lysates of the spleen and brain at 52 hours after stroke by flow cytometry. Splenic gene expression of pro-and anti-inflammatory cytokines was investigated by real-time polymerase chain reaction.
Results

Study Enrollment
All animals except for 1 control (1.4%) survived pMCAO.
One animal of G-CSF+BM MNC 6 hours group was excluded because of partial infarction. Two animals (one in control and one in G-CSF+BM MNC 6 hours) died during day 3 magnetic resonance imaging. Further animals were excluded solely from magnetic resonance imaging because of technical problems (Table II in the online-only Data Supplement) . Finally, 1 animal with G-CSF monotherapy was excluded from behavioral tests because of lack of compliance.
Characterization of Cell Graft
Previously isolated and cryopreserved syngeneic BM MNC grafts were thawed and characterized by flow cytometry. We observed only minor variation of the main leukocyte populations among the different cohorts (n=8 
Peripheral Leukocyte Counts
The impact of G-CSF administration and additional BM MNC transplantation on peripheral leukocyte counts was analyzed 6, 48, 52, 96, and 144 hours after pMCAO. Expectably, G-CSF treatment caused a distinct increase of peripheral leukocyte counts, reaching its peak at 48 hours with a successive normalization until 144 hours after stroke. However, additional administration of BM MNC after either 6 or 48 hours did not impact overall leukocyte counts ( Figure 1 ). The increase of leukocytes was predominantly driven by granulocytes and, to a much lesser extent, by monocytes, T cells, B cells, and natural killer cells (Figure 1 ). Four hours after transplantation of BM MNC at 48 hours, we observed a statistically significant increase of granulocyte counts in the G-CSF+BM MNC 48 hours group compared with the G-CSF monotherapy (Figure 1 ). When comparing leukocyte counts of stroke and naive animals, we observed a considerable decrease of T and B cells, monocytes and natural killer cells 48 hours after stroke. This observation is consistent with recent studies and corresponds to the phenomenon of poststroke immunodepression. 12 Although the suppression of T cells, monocytes, and natural killer cells was limited to 48 hours, we found a persistent depression of B cells (Figure 1) . Interestingly, at 48 hours after stroke, poststroke cellular immunodepression was largely reversed by G-CSF treatment, independent of a concomitant cell therapy. Moreover, G-CSF provoked a significant downregulation of CXCR4 on peripheral blood mononuclear cells at 48 hours (Figure 1 ). CXCR4 expression completely recovered in groups with G-CSF monotherapy or additional early (6 hours) BM MNC administration, but remained suppressed in the G-CSF+BM MNC 48 hours group. Finally, differentiation of T cells into T helper cells, cytotoxic T cells, CD4/CD8 doublepositive, as well as CD4/CD8 double-negative T cells (data not shown) and regulatory T cells ( Figure 1 ) revealed no statistically significant differences among the treatment groups.
Serum Cytokines
Serum concentrations of interleukin (IL)-4, IL-10, IL-17A, monocyte chemotactic protein-1, and macrophage inflammatory protein-1α changed significantly as a function of time (P<0.05), whereas interferon-γ levels remained stable ≤144 hours after stroke ( Figure I in the online-only Data Supplement). At 96 hours, the serum level of macrophage inflammatory protein-1α was slightly but statistically significant reduced by G-CSF+BM MNC 48 hours. Besides that, none of the treatments had significant influence on cytokine levels ( Figure I in the online-only Data Supplement).
Infarct Volume and Brain Edema
At day 1 after stroke, the mean edema-corrected infarct volume (%HLVe) amounted to 15.7±4.5% of the hemisphere without any differences between the experimental groups. Although the infarct volume remained constant during the first week after stroke, we observed a 30% increase of the infarct volume to 19.2±3.7% at day 30 ( Figure 2 ). G-CSF monotherapy or combination therapy had no detectable impact on the infarct volume at any time point. The space-occupying effect of the ischemic lesion (%HSE) was maximally pronounced at day 1 after stroke and successively declined during the first week ( Figure 2 ). At day 30, we measured negative values for %HSE that likely correspond to loss of hemispheric brain tissue and is consistent with the aforementioned increase of infarct volume at the same time point. Neither the early edema-related space-occupying effect nor the delayed brain atrophy was influenced by one of the treatments ( Figure 2 ).
Functional Outcome After Stroke
We next used the adhesive removal test to monitor the clinical course within 30 days after stroke. To clearly define a hypothesis (treatment improves or impairs functional improvement), we a priori decided to perform a summarized analysis of the functional development by means of an area under the curve. At the baseline prior to stroke induction, rats needed ≈5 seconds to notice and remove the sticky tape from their contralateral forelimb. As expected, we observed a substantial increase of the tape removal time after stroke (to 91±37 seconds in the pMCAO-only control), which subsequently declined by ≈50% within 7 days to reach a constant level reflecting the permanent neurological deficit ( Figure 3A ). The area under the curve analysis revealed a statistically significant decrease of the tape removal time in G-CSF and a strong trend in the G-CSF+BM MNC 6 hours group (P=0.05). By contrast, the latter effect was Figure 1 . Influence of experimental treatments on peripheral leukocyte counts. Cell counts from naive spontaneously hypertensive rats (SHR) were included as reference (grey area: upper and lower SD; n=3). All animals that received granulocyte colony-stimulating factor (G-CSF) showed a 3-fold increase of leukocytes at 48 hours that successively normalized until 144 hours. As illustrated by exemplary flow cytometric forward/side scatter (FSC/SSC) plots of blood samples at 48 hours, granulocytes were the main contributors of leukocytosis. At 52 hours, transplantation of bone marrow-derived mononuclear cells (BM MNC) after 48 hours caused a significant increase of granulocytes compared with G-CSF monotherapy. The transient decline of monocytes, T, and natural killer (NK) cells in consequence of stroke was reversed by G-CSF at 48 hours and partly at 96 hours. The suppression of B cells was persistent until 144 hours and was only partially attenuated by G-CSF. The initial decline of CXC chemokine receptor-4 (CXCR4) expression was transient after G-CSF or G-CSF+BM MNC 6 hours, but persistent over the first 144 hours after G-CSF+BM MNC 48 hours. pMCAO indicates permanent right middle cerebral artery occlusion. *P<0.05, **P<0.01, ***P<0.001 compared with control group determined by 1-way ANOVA; n=14 to 17 (48, 96, and 144 hours) or n=3 to 6 (6 and 52 hours) animals per group. Figure 2 . Determination of the corrected hemispheric infarct volume (%HLVe; solid bars) and space-occupying effect (%HSE; striped bars) at day 1, 3, 7, and 30. The %HSE was maximal at day 1 and successively declined until day 7 (ie, brain edema). The increase of %HLVe between days 7 and 30 was accompanied by negative values of %HSE at day 30 (ie, brain atrophy). None of the parameters (corrected lesion volume, brain edema, and brain atrophy) was influenced by any of the treatments; n=11 to 16 animals per group.
Stroke
abolished in the G-CSF+BM MNC 48 hours group ( Figure 3A) . Body weights of all animals completely attained presurgery levels within the following days after stroke. Interestingly, after 30 days, we observed a significant increase of body weight in animals receiving BM MNC at 6 or 48 hours ( Figure 3B ).
Expression of Plasticity-Related Genes and Chronic Inflammation
Next, we investigated the expression of genes that are involved in neural regeneration and delayed inflammation in the ischemic hemisphere. Thirty days after stroke, the expression of Brevican, Neurocan, Gap-43 ( Figure 3C ), Versican, MARCKS, and Slit1 (Table III in the online-only Data Supplement) was not affected by any treatment. The growth factors insulin-like growth factor-1 ( Figure 3C ) and brain-derived neurotrophic factor (Table III in the online-only Data Supplement) showed a 1.5-to 2-fold increase in the ischemic hemisphere, but were not altered by G-CSF or G-CSF+BM MNC. Similarly, expression levels of IL-1β and CD45 were increased in the ischemic hemisphere 30 days after stroke, but did not differ among the experimental groups ( Figure 3C ). Immunohistochemical investigation revealed numerous T cells in the ischemic lesion 30 days after pMCAO, most of them located in the cortical infarct border. Neither G-CSF monotherapy nor cotransplantation of BM MNC altered T-cell counts in the ischemic brain ( Figure 3D ).
Short-Term Effects of Delayed Combination Treatment
Finally, we tried to elucidate the mechanisms behind the antagonizing effect of late BM MNC transplantation on the protective effect of G-CSF. Therefore, BM MNC were stained by the lipophilic membrane dye PKH26 to track short-term biodistribution. Labeling efficiency was 99.3±0.08% (n=3), and the dye had no impact on composition or vitality of the graft (data not shown). Four hours after intravenous transplantation of labeled BM MNC, we could identify PKH26 + cells in all samples investigated (blood, spleen, BM, and brain tissue; Table) . The composition of recovered PKH26 + cells varied from the original graft, indicating differences in biodistribution or survival among the BM MNC subpopulations ( Figure 4A ). In the spleen, numerous PKH26 + cells were found in the marginal zone between red and white pulp ( Figure 4A Figure 4B ). By contrast, we observed a G-CSF-related increase of IL-1β mRNA ( Figure 4B ). Gene expression of chemokine (CC motif) ligand 6, chemokine (CXC motif) ligand 2, chemokine (CXC motif) ligand 5, highmobility group box 1, IL-6, and tumor necrosis factor-α did not differ among the treatment groups (Table IV in the onlineonly Data Supplement). Spleen weights were significantly increased by G-CSF treatment, but not further influenced by BM MNC transplantation (control 530±23 mg versus G-CSF 640±41 mg versus G-CSF+BM MNC 48 hours, 629±14 mg; P<0.05 by 1-way ANOVA). Flow cytometric analyses exposed that the increased spleen weights were primarily caused by a tremendous increase of splenic granulocytes in both groups receiving G-CSF. The latter effect was most pronounced after BM MNC transplantation at 48 hours ( Figure 4C ). By using an annexin V/7-aminoactinomycin D flow cytometric assay, we found most of the splenic granulocytes being vital. A small fraction of necrotic granulocytes was also increased by BM MNC when compared with the G-CSF group ( Figure 4C ). Finally, we quantified immune cells within the ischemic ( Figure 4D ) and contralateral hemisphere ( Figure III in the online-only Data Supplement) 52 hours after experimental stroke. Transplantation of BM MNC after 48 hours caused a significant increase of vital granulocytes in the ischemic hemisphere when compared with the G-CSF or control group ( Figure 4D ). Interestingly, almost half of all granulocytes in the ischemic brain were early apoptotic; however, neither G-CSF monotherapy nor BM MNC cotransplantation had an effect on the extent of this fraction ( Figure 4D ).
Discussion
In this study, we aimed to investigate the potential synergistic effect of 2 successfully tested experimental treatments for stroke: the repeated injection of G-CSF combined with transplantation of BM MNC. Our study yielded 3 major findings: first, we observed that G-CSF, neither alone nor in combination with BM MNC, had any impact on our primary end point, the infarct volume. Second, we found that a monotherapy with G-CSF and the cotransplantation of BM MNC after 6 hours significantly improved functional recovery. Surprisingly, this effect was entirely abolished when BM MNC were given after 48 hours. Finally, we found that G-CSF with and without auxiliary cell therapy significantly altered systemic immune responses to stroke.
The neuroprotective effect of G-CSF has been discovered and mechanistically defined in a landmark study by Schneider et al, 13 who showed that G-CSF provides strong antiapoptotic effects in neurons exposed to ischemia. Many studies reproduced this finding and 2 meta-analyses consistently confirmed a significant impact of G-CSF on the infarct volume, the most frequently used surrogate for neuroprotection. 2, 3 Interestingly, the same meta-analysis revealed, in contrast to one recent study, 14 that the infarct volume was not influenced by G-CSF treatment in permanent stroke, 2 likely owing to the fact that the neuroprotective time window is shorter in permanent stroke (3 hours) compared with the classical ischemia/ reperfusion models (up to 12 hours). 15 In SHR, neuroprotection is even limited to the first 60 minutes after MCAO. 16 We hence reasoned that the lack of influence of G-CSF treatment and cell transplantation on the ischemic lesion is likely caused by the absence of reperfusion and the comorbidities present in SHR. Conversely, the functional effect of G-CSF observed in our study is likely mediated by mechanism beyond neuroprotection. This is highly relevant for translational stroke research, 11, 15 but it should also be noted that inbred SHR may be compromised by genetic aberrations that could bias the value of our experiment.
G-CSF has an impact on various pathophysiological aspects relevant for stroke outcome: it promotes endogenous neurogenesis and angiogenesis, modulates immune responses, reduces brain edema, and enhances structural and functional regeneration capacities of the central nervous system. 17 These mechanisms could explain the significant functional improvement after G-CSF treatment that was prevalent in most of the published preclinical experiments 2,3 being corroborated by ours. Angiogenesis and neurogenesis were not investigated here. However, we examined the expression of various growth-promoting and growth-inhibiting genes during the late stage of poststroke axonal sprouting 18 (day 30) but found no differences between any treatment regime and control. Furthermore, and again in contrast to another study using a reperfusion model of stroke, 19 we found that the brain edema was also not influenced by G-CSF.
With respect to the early functional improvement observed in our study, we suggest acute immunologic interactions as one key mechanism for the efficacy of G-CSF and its antagonization by late BM MNC transplantation. Two days after stroke, we found a significant decline of circulating CXCR4 + mononuclear cells in all treatment groups, likely as a consequence of chemokine receptor downregulation by G-CSF. 20 Recent studies showed that early CXCR4 antagonism significantly improved outcome after stroke by regulating the infiltration of leukocytes into the ischemic brain. 21 In this manner, G-CSF may dampen central nervous system inflammation and damage, and in fact, we found a strong trend toward less macrophages/dendritic cells infiltrating the ischemic lesion in G-CSF-treated animals.
Interestingly, we found a recovery of depressed spleen weights and circulating leukocyte counts in all groups receiving G-CSF. Postischemic immunodepression is a consequence of an overactivated cholinergic anti-inflammatory pathway finally contributing to morbidity after stroke. 12 We found no evidence for infections, such as increased mortality or decreased body weights in our study, but the restoration of immunocompetence by G-CSF may have protected the brain from chronic central nervous system inflammation. 22 In fact, we found ongoing immune responses including an accumulation of T cells at the infarct border at day 30 after stroke, but T-cell counts and brain atrophy were not influenced by G-CSF treatment or accompanying cell therapy.
One surprising finding of our study was that transplantation of BM MNC after 48 hours completely neutralized the beneficial effect of G-CSF. Early transplantation of BM MNC after transient stroke in SHR have had no positive or negative impact on functional outcome 23 ; however, it is possible that late BM MNC transplantation is detrimental after stroke and simply deleted the protective effects of the accompanying G-CSF therapy. This notion remains hypothetical because we did not investigate the exclusive effect of late BM MNC transplantation here. Nevertheless, adverse effects of BM-derived cells have been described in animal models of diabetes mellitus and arteriosclerosis, 24, 25 suggesting a compromised cell graft under translationally relevant conditions of hyperglycemia and hypertension. 26, 27 We found almost 30% of the BM MNC being apoptotic before transplantation, a finding that may reflect hypertension-related oxidative stress in the BM. 26, 27 In steady state, circulating apoptotic cells were trapped by specialized splenic macrophages in the marginal zone between red and white pulp. 28 This endogenous scavenging system carefully downregulates immune-stimulatory functions and helps to maintain self-tolerance. 29 It is thus tempting to speculate that the intravenous transplantation of numerous (pre)apoptotic BM MNC may induce endogenous anti-inflammatory programs, 30, 31 and in fact, we found an accumulation of BM MNC in the splenic marginal zones together with increased expression of antiinflammatory mediators.
Intriguingly, this assumed universal mechanism for intravenously administered cells may also explain the interaction effect between late BM MNC and G-CSF found in our study. Circulating granulocytes have a short half-life and are continuously cleared in the splenic marginal zone. Mice deficient for marginal zone macrophages develop increased granulocyte counts and IL-1β levels. 32 Accordingly, we found that treatment with G-CSF caused a 10-fold increase of splenic granulocytes and 2-fold increase of IL-1β expression, indicating an overload of the granulocyte clearance system. The simultaneous engagement of marginal zone macrophages with transplanted BM MNC and massively increased granulocytes may further overload this scavenging system, as it has been shown after the application of polystyrene particles. 33 This would explain the significant increase of vital granulocytes in the blood, spleen, and brain of animals that received BM MNC at the peak point of G-CSF-induced neutrophilia. Higher neutrophil counts in the brain could finally explain the negative functional effect either by disturbing the microcirculation or by releasing toxic mediators. 34 
Conclusions
In our study, we could confirm the beneficial effect of G-CSF on long-term functional recovery, but not on neuroprotection after stroke in hypertensive rats. The cotreatment with BM MNC was without effect after 6 hours, but reversed the protective effect of G-CSF after 48 hours, probably by overloading the splenic scavenging system by the apoptotic fraction of BM MNC and massively increased granulocytes. 
Supplemental methods
Experimental stroke
Animal experiments were conducted according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), and approved by the appropriate regional authorities (reference number TVV 12/11). A total of 81 spontaneously hypertensive rats (SHR; Charles River, Sulzfeld, Germany) at the age of 12 weeks were anesthetized with ketamine hydrochloride (100mg/kg) and xylazine (10mg/kg) given as an intraperitoneal injection. During the surgical procedure, body core temperature was constantly measured and maintained at 37.5°C. Experimental stroke was induced by permanent occlusion of the right middle cerebral artery (pMCAO) as described previously.
1 Briefly, the right temporal scull bone and dura mater were opened, and the subjacent middle cerebral artery was permanently occluded by thermocoagulation. Health status including the body weight was monitored daily within the first week after stroke and weekly thereafter. The exclusion criteria were defined as follows: i) weight loss of more than 20% body weight during week 1; ii) absence of a cortical brain lesion typical for distal MCAO in the MR sequence; iii) incomplete injection of G-CSF, cell suspension or vehicle solution.
Experimental group allocation
In the first study, we defined the reduction of the infarct volume (%HLVe, see below) by at least 30% as primary endpoint. Accordingly, the sample sizes were a priori calculated for an expected difference of the mean of 30% with α=0.05 and β=0.8 for a one-way ANOVA (Sigma Plot version 11.0). The expected standard deviation (σ=3.2 %HLVe) was obtained from a previous study (day 1 and day 3 after pMCAO from SHRs). 2 SHRs were randomly assigned (balanced randomization by lot) to one of the following experimental groups: (i) G-CSF monotherapy group (henceforth G-CSF, n=18) with a daily intraperitoneal injection of 50 µg/kg Neupogen (rhG-CSF; Amgen GmbH, Thousand Oaks, USA) for 5 days starting 1h after pMCAO; (ii) combination group with early cell transplantation (henceforth G-CSF+BM MNC 6h, n=18) with a G-CSF schedule according to (i) and an additional transplantation of 1.5x10E7 BM MNCs per kg bodyweight at 6h after pMCAO; (iii) combination group with late cell transplantation (henceforth G-CSF+BM MNC 48h, n=18) with a G-CSF schedule according to (i) and an additional transplantation of 1.5x10E7 BM MNCs per kg bodyweight at 48h after pMCAO; (iv) control group (henceforth control, n=18) receiving phosphate buffered saline (PBS) instead of G-CSF and BM MNCs. The administrations in all treatment groups were completely controlled by PBS injections, meaning, for instance, that the G-CSF group received PBS injections at 6h and 48h after stroke. In the second study, we investigated the distribution of PKH26-labeled BM MNC and the short-term immunological responses to late transplantation of BM MNC (48h). Nine animals were randomly assigned to the following experimental groups (in accordance with the first study): (i) G-CSF, n=3; (iii) G-CSF+BM MNC 48h, n=3; (iv) control group, n=3.
